Key result
Glibenclamide reduces resting coronary blood flow by ~17%, whereas selective mitochondrial K(ATP) blockade has no effect.
Why the study?
It was unclear whether the decrease in myocardial oxygen consumption caused by glibenclamide results from primary mitochondrial K(ATP) channel blockade or secondary coronary vessel constriction.
Glibenclamide reduces MVO2 via coronary vasoconstriction, not mitochondrial KATP blockade; leaves open their role in respiration during high ATP demand.
Opening of mitochondrial ATP-sensitive potassium (K(ATP)) channels has been postulated to prevent inhibition of respiration resulting from matrix contraction during high rates of ATP synthesis. Glibenclamide, which blocks K(ATP) channels on the sarcolemma of vascular smooth muscle cells and myocardial myocytes as well as on the inner mitochondrial membrane, results in a decrease of myocardial oxygen consumption (MVO2) both at rest and during exercise. This study examined whether this represents a primary effect of blockade of mitochondrial K(ATP) channels or occurs secondary to coronary resistance vessel constriction with a decrease of coronary blood flow (CBF) and myocardial oxygen availability. MVO2 was measured at rest and during treadmill exercise in 10 dogs during control conditions, after selective mitochondrial K(ATP) channel blockade with 5-hydroxydecanoate (5-HD), and after nonselective K(ATP) channel blockade with glibenclamide. During control conditions, exercise resulted in progressive increases of CBF and MVO2. Glibenclamide (50 microg x kg(-1) x min(-1) ic) resulted in a 17 +/- 6% decrease of resting CBF with a downward shift of CBF during exercise and a decrease of coronary venous PO2, indicating increased myocardial oxygen extraction. In contrast with the effects of glibenclamide, 5-HD (0.7 mg x kg(-1) x min(-1) ic) had no effect on CBF, MVO2, or myocardial oxygen extraction. These findings suggest that glibenclamide decreased MVO2 by causing resistance vessel constriction with a decrease of CBF and oxygen available to the myocardium rather than to a primary reduction of mitochondrial respiration.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2001) studied this question. 5-hydroxydecanoate (5-HD) and glibenclamide vs. Control conditions was evaluated on Myocardial oxygen consumption (MVO2) and coronary blood flow (CBF). In dogs, nonselective K(ATP) channel blockade with glibenclamide decreased resting coronary blood flow by 17%, whereas selective mitochondrial blockade with 5-HD had no effect on CBF or MVO2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: